Mette S. van Ramshorst

1.1k total citations
20 papers, 586 citations indexed

About

Mette S. van Ramshorst is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mette S. van Ramshorst has authored 20 papers receiving a total of 586 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 12 papers in Cancer Research and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mette S. van Ramshorst's work include Breast Cancer Treatment Studies (12 papers), HER2/EGFR in Cancer Research (12 papers) and Cancer Treatment and Pharmacology (10 papers). Mette S. van Ramshorst is often cited by papers focused on Breast Cancer Treatment Studies (12 papers), HER2/EGFR in Cancer Research (12 papers) and Cancer Treatment and Pharmacology (10 papers). Mette S. van Ramshorst collaborates with scholars based in Netherlands, South Africa and Germany. Mette S. van Ramshorst's co-authors include Gabe S. Sonke, Sabine C. Linn, Erik van Werkhoven, Jelle Wesseling, Ingrid A.M. Mandjes, Marie-Jeanne TFD Vrancken Peeters, Aafke H. Honkoop, Inge Kemper, Irma M. Oving and Vincent O. Dezentjé and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Mette S. van Ramshorst

20 papers receiving 580 citations

Peers

Countries citing papers authored by Mette S. van Ramshorst

Since Specialization

Citations

This map shows the geographic impact of Mette S. van Ramshorst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mette S. van Ramshorst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mette S. van Ramshorst more than expected).

Fields of papers citing papers by Mette S. van Ramshorst

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mette S. van Ramshorst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mette S. van Ramshorst. The network helps show where Mette S. van Ramshorst may publish in the future.

Co-authorship network of co-authors of Mette S. van Ramshorst

This figure shows the co-authorship network connecting the top 25 collaborators of Mette S. van Ramshorst. A scholar is included among the top collaborators of Mette S. van Ramshorst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mette S. van Ramshorst. Mette S. van Ramshorst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	429P Brain imaging screening (BIS) in metastatic breast cancer (MBC): Patients’ and physicians’ perspectives 2024 ·Annals of Oncology ·(unknown), Mette S. van Ramshorst, Klaus-Robert Müller, Elisa Agostinetto, Sabine C. Linn, (unknown), (unknown), (unknown), (unknown), Carmen Criscitiello, (unknown), Gilberto Morgan, S Brücker, (unknown), Renate Haidinger, (unknown), (unknown), Francesco Schettini, (unknown)	1
2	BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer 2023 ·Breast Cancer Research ·Marte C. Liefaard, Anna van der Voort, Mette S. van Ramshorst, Joyce Sanders, (unknown), Hugo M. Horlings, Sabine Siesling, Linda de Munck, (unknown), Miranda Kleijn, Lorenza Mittempergher, (unknown), Annuska M. Glas, Jelle Wesseling, Esther H. Lips, Gabe S. Sonke	3
3	Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival 2022 ·The Breast ·Anna van der Voort, Marte C. Liefaard, Mette S. van Ramshorst, Erik van Werkhoven, Joyce Sanders, Jelle Wesseling, Astrid N. Scholten, Marie Jeanne T. F. D. Vrancken Peeters, Linda de Munck, Sabine Siesling, Gabe S. Sonke	7
4	Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer 2021 ·Breast Cancer Research and Treatment ·Emma J. Groen, Marieke E. M. van der Noordaa, Michael Schaapveld, Gabe S. Sonke, Ritse M. Mann, Mette S. van Ramshorst, Esther H. Lips, Marie-Jeanne T. F. D. Vrancken Peeters, Frederieke van Duijnhoven, Jelle Wesseling	6
5	Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of DualERBB2Blockade in Patients WithERBB2-Positive Breast Cancer 2021 ·JAMA Oncology ·Anna van der Voort, Mette S. van Ramshorst, Erik van Werkhoven, Ingrid A.M. Mandjes, Inge Kemper, Annelie Vulink, Irma M. Oving, Aafke H. Honkoop, Lidwine W. Tick, Agnès J. van de Wouw, Caroline M.P.W. Mandigers, Laurence J. van Warmerdam, Jelle Wesseling, Marie-Jeanne TFD Vrancken Peeters, Sabine C. Linn, Gabe S. Sonke	76
6	Adjuvant chemotherapy in small node-negative triple-negative breast cancer 2020 ·European Journal of Cancer ·Tessa G. Steenbruggen, Erik van Werkhoven, Mette S. van Ramshorst, Vincent O. Dezentjé, Marleen Kok, Sabine C. Linn, Sabine Siesling, Gabe S. Sonke	28
7	Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial. 2020 ·Journal of Clinical Oncology ·Anna van der Voort, Mette S. van Ramshorst, Erik van Werkhoven, Ingrid A.M. Mandjes, Inge Kemper, Annelie Vulink, Irma M. Oving, Aafke H. Honkoop, Lidwine W. Tick, Agnès J. van de Wouw, Caroline M.P.W. Mandigers, L.J.C. van Warmerdam, Jelle Wesseling, Marie-Jeanne T. F. D. Vrancken Peeters, Sabine C. Linn, Gabe S. Sonke, (unknown)	24
8	Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore 2019 ·Clinical Cancer Research ·Tessa G. Steenbruggen, Maartje van Seijen, (unknown), Mette S. van Ramshorst, Erik van Werkhoven, (unknown), Jelle Wesseling, Esther H. Lips, Gabe S. Sonke	16
9	Adjuvant chemotherapy in small node-negative triple-negative breast cancer (TNBC). 2019 ·Journal of Clinical Oncology ·Tessa G. Steenbruggen, Mette S. van Ramshorst, Erik van Werkhoven, Vincent O. Dezentjé, Sabine Siesling, Sabine C. Linn, Gabe S. Sonke	3
10	Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial 2018 ·The Lancet Oncology ·Mette S. van Ramshorst, Anna van der Voort, Erik van Werkhoven, Ingrid A.M. Mandjes, Inge Kemper, Vincent O. Dezentjé, Irma M. Oving, Aafke H. Honkoop, Lidwine W. Tick, Agnès J. van de Wouw, Caroline M.P.W. Mandigers, Laurence J. van Warmerdam, Jelle Wesseling, Marie-Jeanne TFD Vrancken Peeters, Sabine C. Linn, Gabe S. Sonke	245
11	Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer 2017 ·Cancer Imaging ·Mette S. van Ramshorst, (unknown), Bas B. Koolen, Kenneth E. Pengel, Kenneth G. A. Gilhuijs, Jelle Wesseling, Sjoerd Rodenhuis, Renato A. Valdés Olmos, Emiel J. Rutgers, Wouter V. Vogel, Gabe S. Sonke, Marie-Jeanne TFD Vrancken Peeters	10
12	A phase III trial of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2+ breast cancer: The TRAIN-2 study (BOOG 2012-03). 2017 ·Journal of Clinical Oncology ·Mette S. van Ramshorst, Erik van Werkhoven, Ingrid A.M. Mandjes, Inge Kemper, Vincent O. Dezentjé, Irma M. Oving, Aafke H. Honkoop, Lidwine W. Tick, (unknown), Caroline M.P.W. Mandigers, Jelle Wesseling, Marie‐Jeanne Vrancken Peeters, Sabine C. Linn, Gabe S. Sonke	5
13	Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies 2017 ·Drugs ·Tessa G. Steenbruggen, Mette S. van Ramshorst, Marleen Kok, Sabine C. Linn, Carolien H. Smorenburg, Gabe S. Sonke	40
14	Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study 2017 ·European Journal of Cancer ·Mette S. van Ramshorst, Erik van Werkhoven, Ingrid A.M. Mandjes, Margaret Schot, Jelle Wesseling, Marie-Jeanne T.F.D. Vrancken Peeters, Jetske M. Meerum Terwogt, Monique E.M.M. Bos, Hendrika M. Oosterkamp, Sjoerd Rodenhuis, Sabine C. Linn, Gabe S. Sonke	18
15	MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy 2017 ·Breast Cancer Research and Treatment ·Mette S. van Ramshorst, Claudette E. Loo, (unknown), (unknown), Jelle Wesseling, Frederieke van Duijnhoven, Marie-Jeanne TFD Vrancken Peeters, Gabe S. Sonke	32
16	The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer 2016 ·Breast Cancer Research and Treatment ·Mette S. van Ramshorst, Margriet van der Heiden‐van der Loo, (unknown), Sabine C. Linn, Gabe S. Sonke	27
17	Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study 2016 ·The Breast ·Mette S. van Ramshorst, Erik van Werkhoven, Aafke H. Honkoop, Vincent O. Dezentjé, Irma M. Oving, Ingrid A.M. Mandjes, Inge Kemper, Carolien H. Smorenburg, Jacqueline M. Stouthard, Sabine C. Linn, Gabe S. Sonke	28
18	Clinical assessment of peripheral neuropathy in HIV-infected children on antiretroviral therapy in rural South Africa 2014 ·European Journal of Pediatrics ·Remco P. H. Peters, Mette S. van Ramshorst, Helen Struthers, James McIntyre	9
19	Efavirenz-induced gynecomastia in a prepubertal girl with human immunodeficiency virus infection: a case report 2013 ·BMC Pediatrics ·Mette S. van Ramshorst, (unknown), Helen Struthers, James McIntyre, Remco P. H. Peters	6
20	Blood Lactate in HIV-infected Children on Antiretroviral Therapy in Rural South Africa 2013 ·The Pediatric Infectious Disease Journal ·Mette S. van Ramshorst, Helen Struthers, James McIntyre, Remco P. H. Peters	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact